Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

[Diagnostic and prognostic significance of α-fetoprotein in hepatocellular carcinoma].

Becker-Assmann J, Fard-Aghaie MH, Kantas A, Makridis G, Reese T, Wagner KC, Petersen J, Buggisch P, Stang A, von Hahn T, Oldhafer KJ.

Chirurg. 2020 Feb 6. doi: 10.1007/s00104-020-01118-6. [Epub ahead of print] German.

PMID:
32025744
2.

Dilatation Therapy and Demographic Characteristics Significantly Influence the Amount of Propofol for Therapeutic Endoscopic Retrograde Cholangiography.

Schmidt CA, Keil C, Kirstein MM, Lehner F, Manns MP, von Hahn T, Lankisch TO, Voigtländer T.

Int J Hepatol. 2019 Jul 1;2019:4793096. doi: 10.1155/2019/4793096. eCollection 2019.

3.

Endoscopic biliary drainage in patients with cholangiocarcinoma - self-expanding metal versus polyethylene stents.

Voigtländer T, Schweitzer N, von Hahn T, Manns MP, Vogel A, Kirstein MM.

Scand J Gastroenterol. 2019 May;54(5):640-645. doi: 10.1080/00365521.2019.1614661. Epub 2019 May 24.

PMID:
31122083
4.

Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells.

Dias J, Hengst J, Parrot T, Leeansyah E, Lunemann S, Malone DFG, Hardtke S, Strauss O, Zimmer CL, Berglin L, Schirdewahn T, Ciesek S, Marquardt N, von Hahn T, Manns MP, Cornberg M, Ljunggren HG, Wedemeyer H, Sandberg JK, Björkström NK.

J Hepatol. 2019 Aug;71(2):301-312. doi: 10.1016/j.jhep.2019.04.009. Epub 2019 May 14.

PMID:
31100314
5.

Delayed onset of smooth muscle cell differentiation leads to hydroureter formation in mice with conditional loss of the zinc finger transcription factor gene Gata2 in the ureteric mesenchyme.

Weiss AC, Bohnenpoll T, Kurz J, Blank P, Airik R, Lüdtke TH, Kleppa MJ, Deuper L, Kaiser M, Mamo TM, Costa R, von Hahn T, Trowe MO, Kispert A.

J Pathol. 2019 Aug;248(4):452-463. doi: 10.1002/path.5270. Epub 2019 Apr 30.

PMID:
30916783
6.

Characterization of the Filovirus-Resistant Cell Line SH-SY5Y Reveals Redundant Role of Cell Surface Entry Factors.

Zapatero-Belinchón FJ, Dietzel E, Dolnik O, Döhner K, Costa R, Hertel B, Veselkova B, Kirui J, Klintworth A, Manns MP, Pöhlmann S, Pietschmann T, Krey T, Ciesek S, Gerold G, Sodeik B, Becker S, von Hahn T.

Viruses. 2019 Mar 19;11(3). pii: E275. doi: 10.3390/v11030275.

7.

Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers.

Sandmann L, Dörge P, Wranke A, Vermehren J, Welzel TM, Berg CP, Grottenthaler JM, Weiss KH, Langel J, Sterneck M, von Wulffen M, Manns MP, Wedemeyer H, Hardtke S, von Hahn T.

Eur J Gastroenterol Hepatol. 2019 Aug;31(8):1049-1056. doi: 10.1097/MEG.0000000000001386.

PMID:
30807443
8.

[Diseases and diagnosis of the biliary system : When does the gastroenterologist need the radiologist?]

von Hahn T, Ringe KI, Potthoff A.

Radiologe. 2019 Apr;59(4):293-299. doi: 10.1007/s00117-019-0501-1. Review. German.

PMID:
30806734
9.

Expression Cloning of Host Factors Required for the HCV Replication Cycle.

Ciesek S, von Hahn T.

Methods Mol Biol. 2019;1911:169-182. doi: 10.1007/978-1-4939-8976-8_11.

PMID:
30593625
10.

SEC14L2, a lipid-binding protein, regulates HCV replication in culture with inter- and intra-genotype variations.

Costa R, Todt D, Zapatero-Belinchón F, Schenk C, Anastasiou OE, Walker A, Hertel B, Timmer L, Bojkova D, Ruckert M, Sarrazin C, Timm J, Lohmann V, Manns MP, Steinmann E, von Hahn T, Ciesek S.

J Hepatol. 2019 Apr;70(4):603-614. doi: 10.1016/j.jhep.2018.11.012. Epub 2018 Nov 23.

PMID:
30472319
11.

Role of BK polyomavirus (BKV) and Torque teno virus (TTV) in liver transplant recipients with renal impairment.

Herrmann A, Sandmann L, Adams O, Herrmann D, Dirks M, Widera M, Westhaus S, Kaiser R, di Cristanziano V, Manns MP, Korth J, Richter N, Anastasiou O, Timm J, von Hahn T, Ciesek S.

J Med Microbiol. 2018 Oct;67(10):1496-1508. doi: 10.1099/jmm.0.000823. Epub 2018 Aug 23.

PMID:
30136921
12.

Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.

Grottenthaler JM, Werner CR, Steurer M, Spengler U, Berg T, Engelmann C, Wedemeyer H, von Hahn T, Stremmel W, Pathil A, Seybold U, Schott E, Blessin U, Sarrazin C, Welker MW, Harrer E, Scholten S, Hinterleitner C, Lauer UM, Malek NP, Berg CP.

PLoS One. 2018 Jun 6;13(6):e0197544. doi: 10.1371/journal.pone.0197544. eCollection 2018.

13.

Transjugular diagnostics in acute liver failure including measurements of hepatocentral venous biomarker gradients.

Wang MC, Wandrer F, Schlué J, Voigtländer T, Lankisch TO, Manns MP, Bantel H, von Hahn T.

Hepatol Res. 2018 Oct;48(11):914-925. doi: 10.1111/hepr.13185. Epub 2018 Jun 5.

PMID:
29726061
14.

Very low rates of Helicobacter pylori infection in organ transplant recipients presenting with peptic ulcer disease.

Thiele T, Manns MP, Lankisch TO, von Hahn T.

Acta Gastroenterol Belg. 2017 Jan-Mar;80(1):25-30.

PMID:
29364094
15.

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.

Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C; European HCV Resistance Study Group.

Gastroenterology. 2018 Mar;154(4):976-988.e4. doi: 10.1053/j.gastro.2017.11.007. Epub 2017 Nov 13.

PMID:
29146520
16.

Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load.

Westhaus S, Deest M, Nguyen ATX, Stanke F, Heckl D, Costa R, Schambach A, Manns MP, Berg T, Vondran FWR, Sarrazin C, Ciesek S, von Hahn T.

J Hepatol. 2017 Aug;67(2):237-245. doi: 10.1016/j.jhep.2017.03.020. Epub 2017 Mar 29.

PMID:
28363797
17.

A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection.

Buchmann B, Döhner K, Schirdewahn T, Sodeik B, Manns MP, Wedemeyer H, Ciesek S, von Hahn T.

Antiviral Res. 2017 May;141:116-123. doi: 10.1016/j.antiviral.2017.02.008. Epub 2017 Feb 20.

PMID:
28223128
18.

[Acute hemorrhage in the upper gastrointestinal tract].

Busch M, Schneider A, Lankisch T, von Hahn T.

Internist (Berl). 2017 Mar;58(3):226-232. doi: 10.1007/s00108-016-0184-x. Review. German.

PMID:
28108748
19.

Prevention strategies for blood-borne viruses-in the Era of vaccines, direct acting antivirals and antiretroviral therapy.

Pfaender S, von Hahn T, Steinmann J, Ciesek S, Steinmann E.

Rev Med Virol. 2016 Sep;26(5):330-9. doi: 10.1002/rmv.1890. Epub 2016 May 17. Review.

20.

Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.

Ciesek S, Proske V, Otto B, Pischke S, Costa R, Lüthgehetmann M, Polywka S, Klempnauer J, Nashan B, Manns MP, von Hahn T, Lohse AW, Wedemeyer H, Mix H, Sterneck M.

Transpl Infect Dis. 2016 Jun;18(3):326-32. doi: 10.1111/tid.12524. Epub 2016 May 10.

PMID:
26988272
21.

Erratum to: Comparison of Technical and Clinical Outcome of Transjugular Portosystemic Shunt Placement Between a Bare Metal Stent and a PTFE-Stentgraft Device.

Lauermann J, Potthoff A, Mc Cavert M, Marquardt S, Vaske B, Rosenthal H, von Hahn T, Wacker F, Meyer BC, Rodt T.

Cardiovasc Intervent Radiol. 2016 Apr;39(4):635-6. doi: 10.1007/s00270-015-1262-5. No abstract available.

PMID:
26662291
22.

Cationic amphiphilic drugs enhance entry of lentiviral particles pseudotyped with rabies virus glycoprotein into non-neuronal cells.

Klintworth A, Nolden T, Westhaus S, Rohrmann K, David S, Manns MP, Finke S, Ciesek S, von Hahn T.

Antiviral Res. 2015 Dec;124:122-31. doi: 10.1016/j.antiviral.2015.10.017. Epub 2015 Nov 2.

PMID:
26542648
23.

Comparison of Technical and Clinical Outcome of Transjugular Portosystemic Shunt Placement Between a Bare Metal Stent and a PTFE-Stentgraft Device.

Lauermann J, Potthoff A, Mc Cavert M, Marquardt S, Vaske B, Rosenthal H, von Hahn T, Wacker F, Meyer BC, Rodt T.

Cardiovasc Intervent Radiol. 2016 Apr;39(4):547-56. doi: 10.1007/s00270-015-1209-x. Epub 2015 Sep 24. Erratum in: Cardiovasc Intervent Radiol. 2016 Apr;39(4):635-6.

PMID:
26404629
24.

Cyclophilin polymorphism and virus infection.

von Hahn T, Ciesek S.

Curr Opin Virol. 2015 Oct;14:47-9. doi: 10.1016/j.coviro.2015.07.012. Epub 2015 Aug 13. Review.

PMID:
26281011
25.

Host cell mTORC1 is required for HCV RNA replication.

Stöhr S, Costa R, Sandmann L, Westhaus S, Pfaender S, Anggakusuma, Dazert E, Meuleman P, Vondran FW, Manns MP, Steinmann E, von Hahn T, Ciesek S.

Gut. 2016 Dec;65(12):2017-2028. doi: 10.1136/gutjnl-2014-308971. Epub 2015 Aug 14.

26.

Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators.

Van ND, Falk CS, Sandmann L, Vondran FW, Helfritz F, Wedemeyer H, Manns MP, Ciesek S, von Hahn T.

Gut. 2016 Jun;65(6):1015-23. doi: 10.1136/gutjnl-2014-308003. Epub 2015 Mar 23.

27.

Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection.

Solbach P, Westhaus S, Deest M, Herrmann E, Berg T, Manns MP, Ciesek S, Sarrazin C, von Hahn T.

Cell Mol Gastroenterol Hepatol. 2015 Mar 14;1(3):285-294.e1. doi: 10.1016/j.jcmgh.2015.03.002. eCollection 2015 May.

28.

Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP).

Veloso Alves Pereira I, Buchmann B, Sandmann L, Sprinzl K, Schlaphoff V, Döhner K, Vondran F, Sarrazin C, Manns MP, Pinto Marques Souza de Oliveira C, Sodeik B, Ciesek S, von Hahn T.

PLoS One. 2015 Feb 3;10(2):e0117152. doi: 10.1371/journal.pone.0117152. eCollection 2015.

29.

The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry.

Gehring G, Rohrmann K, Atenchong N, Mittler E, Becker S, Dahlmann F, Pöhlmann S, Vondran FW, David S, Manns MP, Ciesek S, von Hahn T.

J Antimicrob Chemother. 2014 Aug;69(8):2123-31. doi: 10.1093/jac/dku091. Epub 2014 Apr 7.

PMID:
24710028
30.

Ultrasound presentation of abdominal tuberculosis in a German tertiary care center.

von Hahn T, Bange FC, Westhaus S, Rifai K, Attia D, Manns M, Potthoff A, Gebel M.

Scand J Gastroenterol. 2014 Feb;49(2):184-90. doi: 10.3109/00365521.2013.865258. Epub 2013 Dec 11.

PMID:
24325727
31.

Hepatitis C virus core antigen testing in liver and kidney transplant recipients.

Heidrich B, Pischke S, Helfritz FA, Mederacke I, Kirschner J, Schneider J, Raupach R, Jäckel E, Barg-Hock H, Lehner F, Klempnauer J, von Hahn T, Cornberg M, Manns MP, Ciesek S, Wedemeyer H.

J Viral Hepat. 2014 Nov;21(11):769-79. doi: 10.1111/jvh.12204. Epub 2013 Nov 19.

PMID:
24251818
32.

Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization.

Deest M, Westhaus S, Steinmann E, Manns MP, von Hahn T, Ciesek S.

Antiviral Res. 2014 Jan;101:37-44. doi: 10.1016/j.antiviral.2013.10.018. Epub 2013 Nov 7.

PMID:
24211330
33.

Novel therapies for hepatitis C - one pill fits all?

Manns MP, von Hahn T.

Nat Rev Drug Discov. 2013 Aug;12(8):595-610. doi: 10.1038/nrd4050. Epub 2013 Jun 28. Review.

PMID:
23807378
34.

Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission.

Catanese MT, Loureiro J, Jones CT, Dorner M, von Hahn T, Rice CM.

J Virol. 2013 Aug;87(15):8282-93. doi: 10.1128/JVI.01102-13. Epub 2013 May 22.

35.

The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies.

Gierer S, Bertram S, Kaup F, Wrensch F, Heurich A, Krämer-Kühl A, Welsch K, Winkler M, Meyer B, Drosten C, Dittmer U, von Hahn T, Simmons G, Hofmann H, Pöhlmann S.

J Virol. 2013 May;87(10):5502-11. doi: 10.1128/JVI.00128-13. Epub 2013 Mar 6.

36.

Characterization of the inhibition of hepatitis C virus entry by in vitro-generated and patient-derived oxidized low-density lipoprotein.

Westhaus S, Bankwitz D, Ernst S, Rohrmann K, Wappler I, Agné C, Luchtefeld M, Schieffer B, Sarrazin C, Manns MP, Pietschmann T, Ciesek S, von Hahn T.

Hepatology. 2013 May;57(5):1716-24. doi: 10.1002/hep.26190. Epub 2013 Feb 15.

PMID:
23212706
37.

[Viral infection of hepatocytes].

von Hahn T.

Dtsch Med Wochenschr. 2012 Nov;137(47):2448-52. doi: 10.1055/s-0032-1327274. Epub 2012 Nov 14. German.

PMID:
23152073
38.

Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro.

Sandmann L, Wilson M, Back D, Wedemeyer H, Manns MP, Steinmann E, Pietschmann T, von Hahn T, Ciesek S.

Antiviral Res. 2012 Oct;96(1):51-8. doi: 10.1016/j.antiviral.2012.07.005. Epub 2012 Jul 24.

PMID:
22842003
39.

Hepatocytes that express variants of cyclophilin A are resistant to HCV infection and replication.

von Hahn T, Schiene-Fischer C, Van ND, Pfaender S, Karavul B, Steinmann E, Potthoff A, Strassburg C, Hamdi N, Abdelaziz AI, Sarrazin C, Müller T, Berg T, Trépo E, Wedemeyer H, Manns MP, Pietschmann T, Ciesek S.

Gastroenterology. 2012 Aug;143(2):439-47.e1. doi: 10.1053/j.gastro.2012.04.053. Epub 2012 May 8.

PMID:
22580540
40.

Arrest all accessories--inhibition of hepatitis C virus by compounds that target host factors.

von Hahn T, Ciesek S, Manns MP.

Discov Med. 2011 Sep;12(64):237-44. Review.

41.

The novel immunosuppressive protein kinase C inhibitor sotrastaurin has no pro-viral effects on the replication cycle of hepatitis B or C virus.

von Hahn T, Schulze A, Chicano Wust I, Heidrich B, Becker T, Steinmann E, Helfritz FA, Rohrmann K, Urban S, Manns MP, Pietschmann T, Ciesek S.

PLoS One. 2011;6(9):e24142. doi: 10.1371/journal.pone.0024142. Epub 2011 Sep 1.

42.

Second-wave protease inhibitors: choosing an heir.

Ciesek S, von Hahn T, Manns MP.

Clin Liver Dis. 2011 Aug;15(3):597-609. doi: 10.1016/j.cld.2011.05.014. Epub 2011 Jun 25. Review.

PMID:
21867939
43.

The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry.

Ciesek S, von Hahn T, Colpitts CC, Schang LM, Friesland M, Steinmann J, Manns MP, Ott M, Wedemeyer H, Meuleman P, Pietschmann T, Steinmann E.

Hepatology. 2011 Dec;54(6):1947-55. doi: 10.1002/hep.24610.

PMID:
21837753
44.

Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany.

von Hahn T, Ciesek S, Wegener G, Plentz RR, Weismüller TJ, Wedemeyer H, Manns MP, Greten TF, Malek NP.

Scand J Gastroenterol. 2011 Sep;46(9):1092-8. doi: 10.3109/00365521.2011.589472. Epub 2011 Jun 22.

PMID:
21692710
45.

Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles.

Ciesek S, Westhaus S, Wicht M, Wappler I, Henschen S, Sarrazin C, Hamdi N, Abdelaziz AI, Strassburg CP, Wedemeyer H, Manns MP, Pietschmann T, von Hahn T.

J Virol. 2011 Aug;85(15):7613-21. doi: 10.1128/JVI.00212-11. Epub 2011 Jun 1.

46.

Survival of the fittest: selection of hepatitis C virus variants during liver graft reinfection.

Mederacke I, Von Hahn T.

Hepatology. 2011 Feb;53(2):705-8. doi: 10.1002/hep.24137. No abstract available.

PMID:
21274891
47.

Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches.

von Hahn T, Steinmann E, Ciesek S, Pietschmann T.

Expert Rev Gastroenterol Hepatol. 2010 Feb;4(1):63-79. doi: 10.1586/egh.09.74. Review.

PMID:
20136590
48.

Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A.

Ciesek S, Steinmann E, Wedemeyer H, Manns MP, Neyts J, Tautz N, Madan V, Bartenschlager R, von Hahn T, Pietschmann T.

Hepatology. 2009 Nov;50(5):1638-45. doi: 10.1002/hep.23281.

PMID:
19821520
49.

Genetic variation in CLDN1 and susceptibility to hepatitis C virus infection.

Bekker V, Chanock SJ, Yeager M, Hutchinson AA, von Hahn T, Chen S, Xiao N, Dotrang M, Brown M, Busch MP, Edlin BR, Rice CM, O'Brien TR.

J Viral Hepat. 2010 Mar;17(3):192-200. doi: 10.1111/j.1365-2893.2009.01166.x. Epub 2009 Aug 7.

50.

Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.

Keck ZY, Li SH, Xia J, von Hahn T, Balfe P, McKeating JA, Witteveldt J, Patel AH, Alter H, Rice CM, Foung SK.

J Virol. 2009 Jun;83(12):6149-60. doi: 10.1128/JVI.00248-09. Epub 2009 Mar 25.

Supplemental Content

Loading ...
Support Center